Catalog No.
Product Name
Application
Product Information
Citations
- Racecadotril is a potent enkephalinase inhibitor which exhibits selective antisecretory activity.
-
neprilysin inhibitor
AHU-377 is an inhibitor of neprilysin with IC50 value of 5nM. -
angiotensin receptor-neprilysin inhibitor
LCZ696 is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. -
metalloendopeptidase inhibitor
Phosphoramidon Disodium Salt is a metalloendopeptidase inhibitor. -
ACE/NEP inhibitor
Omapatrilat is a dual inhibitor of the metalloproteases ACE and NEP with Ki values of 0.64 and 0.45 nM, respectively. -
NEP inhibitor
Sch-42495 racemate is the racemate of Sch-42495. Sch-42495 is a novel neutral metalloendopeptidase (NEP) inhibitor. Sch-42495 is the orally active ethylester prodrug of SCH 42354. - Opiorphin, an opioid peptide, is a potent enkephalin-inactivating zinc ectopeptidases in human inhibitor. Opiorphin inhibits two enkephalin-catabolizing ectoenzymes, human neutral ecto-endopeptidase, hNEP (EC 3.4.24.11) with an IC50 value of 11 μM, and human ecto-aminopeptidase, hAP-N (EC 3.4.11.2). Opiorphin displays potent analgesic activity by activating endogenous opioid-dependent transmission.
-
ACE/NEP Inhibitor
Fasidotril is a dual inhibitor of neprilysin and angiotensin-converting enzyme (ACE). It demonstrates significant biological activity in the modulation of blood pressure and fluid balance, making it a valuable tool in hypertension and congestive heart failure (CHF) research. The compound's ability to inhibit both pathways provides insight into the therapeutic potential for cardiovascular disease management. -
ACE/NEP Inhibitor
AD015 is a dual inhibitor of angiotensin-converting enzyme (ACE) and neprilysin (NEP). It exhibits potent inhibitory activity against NEP, with an IC50 of 0.009 µM, and shows strong inhibition of both nephron ACE (nACE) and cardiac ACE (cACE), with IC50 values of 0.019 µM and 0.0008 µM, respectively. This compound is valuable for research in cardiovascular and renal physiology, particularly in studies related to hypertension and heart failure, where modulation of the renin-angiotensin system is critical. -
NEP Inhibitor
Z-13752A is a mercaptopropanoyl amino acid that functions as an inhibitor of neprilysin (NEP) and angiotensin-converting enzyme (ACE) with Ki values of 1.8 nM and 3.2 nM, respectively. This compound has been shown to effectively reduce arterial blood pressure while enhancing coronary blood flow. Z-13752A is valuable for research focused on coronary artery occlusion and related cardiovascular conditions. -
cACE/NEP Inhibitor
AD011 is a dual inhibitor of carboxypeptidase angiotensin-converting enzyme (cACE) and neprilysin (NEP). This compound is derived from the C-domain selective ACE inhibitor lisinopril-tryptophan and demonstrates significant antihypertensive and cardioprotective effects. AD011 is suitable for research applications focused on cardiovascular health and the modulation of renin-angiotensin system pathways. -
cACE/NEP Inhibitor
AD013 is a dual inhibitor of the enzymes cACE (constitutive Angiotensin-Converting Enzyme) and NEP (Neutral Endopeptidase). This compound is derived from a C-domain selective ACE inhibitor and has demonstrated significant potential in providing antihypertensive and cardioprotective effects. AD013 serves as a valuable reagent for research focused on cardiovascular diseases and hypertension therapies. -
cACE/NEP Inhibitor
AD012 is a dual inhibitor of the enzymes neprilysin (NEP) and angiotensin-converting enzyme (cACE). Designed from the C-domain selective ACE inhibitor, lisinopril-tryptophan, AD012 demonstrates significant antihypertensive and cardioprotective properties. This compound is valuable for research in cardiovascular health and the treatment of hypertension. -
NEP Inhibitor
GW 796406 is a potent neprilysin (NEP) inhibitor with an IC50 value of approximately 1.1-2.5 nM, exhibiting a higher selectivity compared to ACE, which has an IC50 of around 1.6-4.7 nM. This compound is valuable for exploring mechanisms involved in cardiovascular diseases and may aid in the development of therapeutics targeting NEP-related pathways. GW 796406's specificity and efficacy make it a useful tool for researchers studying cardiovascular health and related disorders. -
ACE/NEP Inhibitor
RB-105 is a potent dual inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP), with Ki values of 4.2 nM and 1.7 nM, respectively. By inhibiting ACE, RB-105 decreases angiotensin II production and enhances bradykinin levels, while NEP inhibition further elevates natriuretic peptide levels, resulting in a synergistic increase in bradykinin. This compound exhibits significant antihypertensive and natriuretic effects in both spontaneously hypertensive and normotensive rat models, making RB-105 a valuable reagent for studies on hypertension and related cardiovascular conditions. -
NEP/ACE Inhibitor
Aladotril, a dual inhibitor of neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), exhibits potential in ameliorating cardiac hypertrophy without reducing blood pressure. This compound is valuable for research focused on heart failure and the mechanisms of cardiac remodeling following myocardial infarction. Its unique properties make it an important tool for studying cardiovascular health and therapeutic interventions. -
ACE/ECE-1/NEP Inhibitor
CGS 35601 is a potent inhibitor of endothelin-converting enzyme-1 (ECE-1), neutral endopeptidase 24.11 (NEP), and angiotensin-converting enzyme (ACE), exhibiting IC50 values of 55 nM, 2 nM, and 22 nM, respectively. This compound effectively suppresses pressor responses induced by big endothelin-1 and angiotensin I, while simultaneously enhancing the circulation of atrial natriuretic peptide (ANP). CGS 35601 serves as a valuable tool in cardiovascular research, particularly in delineating the regulatory mechanisms of cardiovascular function in animal models. -
Angiotensin-Converting Enzyme/Neprilysin Inhibitor
Alatrioprilat is an orally active inhibitor of angiotensin-converting enzyme (ACE) and neprilysin, with an IC50 of 19.6 nM for ACE and 6.1 nM for neprilysin. This compound is significant in the metabolism of hormonal peptides, particularly in the degradation of nitric oxide and atrial natriuretic factor (ANF). Alatrioprilat is applicable in cardiovascular disease research, offering insights into therapeutic strategies for conditions influenced by these pathways. -
NEP/APN Inhibitor
Sialorphin targets neprilysin (NEP) and aminopeptidase N (APN) as a potent inhibitor, effectively preventing the degradation of key neuropeptides like Substance P and methionine enkephalin. This compound demonstrates significant biological activity, including analgesic effects, modulation of sexual behavior in male rats, and the alleviation of colitis. Additionally, Sialorphin exhibits low toxicity against specific tumor cells, making it a valuable tool for research into pain management, inflammatory bowel disease, and oncology. -
AT1/NEP Inhibitor
TD-0212 TFA is an orally active dual pharmacology inhibitor targeting the angiotensin II type 1 receptor (AT1) and neprilysin (NEP). With a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP, this compound exhibits significant biological activity in modulating cardiovascular and neuroprotective pathways. TD-0212 TFA is suitable for research applications exploring the roles of AT1 antagonism and neprilysin inhibition in various disease models. -
NEP Inhibitor
Thiorphan is a selective neprilysin (NEP) inhibitor with an IC50 of 6.9 nM. By competitively binding to NEP, Thiorphan inhibits its activity, thereby preventing the degradation of neuropeptides such as substance P and neurokinin A. This compound is particularly relevant in neonatal brain injury research, as it can elevate levels of these neuropeptides, activate NK1 and NK2 receptors, and mitigate excessive NMDA receptor activation, thus providing neuroprotection against excitotoxicity. Additionally, Thiorphan may play a role in studying respiratory diseases through its potential to inhibit NEP-mediated bronchoconstriction. -
NEP Inhibitor
Sacubitril sodium is a potent and orally active neprilysin (NEP) inhibitor, exhibiting an IC50 of 5 nM. By enhancing the activity of the natriuretic peptide (NP) system, it demonstrates significant antihypertensive effects. Sacubitril sodium is not only crucial in heart failure therapy but also serves as a valuable tool for research related to heart failure, hypertension, and COVID-19. -
Neprilysin Inhibitor
Phenylalanylalanine is a dipeptide that acts as a neprilysin inhibitor. This compound plays a significant role in modulating the metabolism of amyloid peptides, making it valuable in neurodegenerative disease research. It can be utilized to explore pathways related to proteolytic processing and may have implications in studies focused on Alzheimer's disease and other conditions linked to proteostasis. -
Neprilysin Inhibitor
Risotilide is a potent neprilysin inhibitor that effectively impedes enkephalinase B activity, with an IC50 value of 0.35 µM. Additionally, it demonstrates strong inhibition of enkephalinase A (IC50 = 0.02 µM) and aminopeptidase activity (IC50 = 13 µM). This comprehensive inhibition profile makes Risotilide a valuable reagent for studying enkephalin biodegradation and its implications in neurobiology and pain management research. -
Neprilysin Inhibitor
Mixanpril is a potent neprilysin inhibitor that significantly modulates insulin sensitivity. In studies using obese Zucker rats, Mixanpril demonstrates the ability to enhance insulin-mediated glucose disposal and effectively regulate femoral blood flow. Its distinct mechanism of action sets it apart from traditional ACE inhibitors, making it a valuable reagent for research in metabolic disorders and cardiovascular physiology. -
Neprilysin Inhibitor
Benproperine is a selective neprilysin inhibitor characterized by its unique N-acyl-L-prolyl-L-valine structure, featuring an α-isobutylsuccinic acid β-hydroxamic acid moiety. This compound exhibits significant biological activity by modulating the degradation of neuropeptides and other substrates of neprilysin. It is utilized in research applications aimed at investigating neurodegenerative diseases and the modulation of neuropeptide signaling pathways. -
NEP Inhibitor
SCH-39370 is a highly selective inhibitor of neutral metalloendopeptidase (NEP), exhibiting an IC50 value of 11.2 nM in rabbit kidney assays. This compound enhances the biological responses to atrial natriuretic factor and demonstrates significant antihypertensive effects in desoxycorticosterone acetate-sodium hypertensive rat models. SCH-39370 is valuable for research on cardiovascular function and the regulation of blood pressure through NEP inhibition. -
NEP Inhibitor
SCH-42354 is a potent, orally active inhibitor of neutral endopeptidase (NEP). This compound enhances the biological activity of atrial natriuretic peptide (ANP) by preventing its hydrolysis, which is crucial for regulating blood pressure. Inhibition studies demonstrate that SCH-42354 exhibits IC50 values of 8.3 nM for leu-enkephalin and 10.0 nM for atrial natriuretic factor (ANF). Its significant antihypertensive activity makes it a valuable tool for cardiovascular research and the study of peptide regulation in clinical applications. -
NEP Inhibitor
(Rac)-UK-414495 is a potent inhibitor of neutral endopeptidase (NEP), a key enzyme involved in peptide regulation. This compound has been shown to enhance cyclic AMP (cAMP) levels in the female genitalia, suggesting its potential role in modulating reproductive physiological processes. Its applicability in research may extend to studies focused on sex-based physiological response and NEP-related pathways. -
NEP Inhibitor
SCH 47896 is a potent and selective inhibitor of neprilysin (NEP), a metalloendopeptidase involved in the degradation of vasoactive peptides. This compound has demonstrated significant biological activity in research applications focused on cardiovascular diseases, particularly hypertension. By inhibiting NEP, SCH 47896 may provide insights into therapeutic strategies aimed at modulating cardiovascular function and improving patient outcomes. -
NEP Inhibitor
UK-447841 is a selective neprilysin (NEP) inhibitor. This compound has been identified for its potential role in modulating neuropeptide levels, making it applicable in studies related to female sexual arousal disorder. Research utilizing UK-447841 may provide insights into the therapeutic modulation of sexual function and related disorders. -
NEP Inhibitor
CGS25155 is a potent inhibitor of neutral endopeptidase 24.11 (NEP 24.11) with an IC50 of 3 nM. By inhibiting NEP, CGS25155 effectively slows the degradation of the cardiac hormone atrial natriuretic peptide (ANP), demonstrating antihypertensive effects in the DOCA-salt induced rat hypertension model. This compound is valuable for research in cardiovascular diseases and the study of peptide metabolism. -
Neprilysin Inhibitor
Dexecadotril is a selective neprilysin (NEP) inhibitor known for its potent biological activity. As a prodrug of the R-enantiomers of Thiorphan, Dexecadotril exhibits significant intestinal antisecretory properties. This reagent is valuable for research exploring the modulation of neuropeptide levels and potential therapeutic applications in conditions related to sodium and fluid balance. -
NEP Inhibitor
SCH-34826 is an orally active neutral metalloendopeptidase (NEP) inhibitor that effectively reduces ANF degradation, thereby enhancing its antihypertensive and diuretic effects. This compound is valuable for research applications in cardiovascular and renal disease studies, allowing for deeper insights into the modulation of fluid balance and blood pressure regulation. -
Neprilysin Inhibitor
NEP-In-1 is a potent inhibitor of neprilysin (NEP), exhibiting an IC50 value of 2 nM for dNEP. This compound effectively modulates the activity of NEP, an enzyme involved in the degradation of bioactive peptides. NEP-In-1 is valuable for research applications investigating neuropeptide signaling pathways and potential therapeutic strategies in neurodegenerative disorders. -
NEP Inhibitor
SCH 42495 is an orally active neutral endopeptidase (NEP) inhibitor that exerts antihypertensive effects. As the ethyl ester proagent of SCH 42354, it is utilized in research applications focused on cardiovascular diseases and the modulation of peptide metabolism. This compound serves as a valuable tool for investigating the role of NEP in various physiological and pathological processes. -
Neprilysin Inhibitor
SQ28603 is a selective inhibitor of neprilysin (NEP), an enzyme involved in the degradation of numerous peptides including atrial natriuretic peptide (ANP). By inhibiting NEP, SQ28603 can enhance the levels of ANP and potentially influence cardiovascular and renal function. This compound is valuable for research into heart failure, hypertension, and other conditions where atrial natriuretic peptide regulation is crucial. -
Neprilysin Inhibitor
NEP-IN-2 is a selective inhibitor of neprilysin, an enzyme involved in the degradation of bioactive peptides. This compound is critical for studying its role in the context of cardiovascular diseases such as atherosclerosis and restenosis. Researchers can utilize NEP-IN-2 to investigate the effects of neprilysin inhibition on cell proliferation and related signaling pathways in these disease models. -
NEP Inhibitor
CGS 24592 is a selective and potent inhibitor of neutral endopeptidase 24.11 (NEP), exhibiting an IC50 value of 1.6 nmol/L. This compound effectively decreases the degradation of atrial natriuretic peptide (ANP), leading to increased plasma levels of ANP and subsequent reduction in blood pressure. CGS 24592 is valuable for research in cardiovascular diseases, particularly in the contexts of hypertension and congestive heart failure.
